SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

NCT00577382 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Mucosal Lentiginous Melanoma
Acral Lentiginous Malignant Melanoma

Interventions

DRUG: Sunitinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]